{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:40:09Z","timestamp":1794249609506,"version":"4.9.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.annonc.2024.05.541","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T21:03:35Z","timestamp":1719435815000},"page":"805-816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a\u00a0secondary analysis from MARIPOSA"],"prefix":"10.1016","volume":"35","author":[{"given":"E.","family":"Felip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-8189","authenticated-orcid":false,"given":"B.","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.I.","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Califano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-5138","authenticated-orcid":false,"given":"J.C.-H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9080-4747","authenticated-orcid":false,"given":"S.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5037-0523","authenticated-orcid":false,"given":"Y.J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Danchaivijitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.G.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.N.","family":"Sendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.-C.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Prabhash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Stroyakovskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Rodriguez-Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.G.","family":"Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-2271","authenticated-orcid":false,"given":"D.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gottfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dooms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7575-3870","authenticated-orcid":false,"given":"A.","family":"Passaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-3394","authenticated-orcid":false,"given":"M.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.Z.","family":"Gelatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Perdrizet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1764-4975","authenticated-orcid":false,"given":"S.-H.I.","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4056","authenticated-orcid":false,"given":"J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gormley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fennema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Daksh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Bauml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2024.05.541_bib1","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1158\/1078-0432.CCR-22-0741","article-title":"Circulating tumor DNA kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)","volume":"28","author":"Mack","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.05.541_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.21037\/tlcr.2020.03.17","article-title":"Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort","volume":"9","author":"Song","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.annonc.2024.05.541_bib3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cllc.2020.11.001","article-title":"Predictive and prognostic potential of TP53 in patients with advanced non-small-cell lung cancer treated with EGFR-TKI: analysis of a phase III randomized clinical trial (CTONG 0901)","volume":"22","author":"Li","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.annonc.2024.05.541_bib4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cllc.2017.04.015","article-title":"Characterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: a multicenter study","volume":"18","author":"Jiang","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.annonc.2024.05.541_bib5","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1038\/s41598-024-56046-w","article-title":"Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases","volume":"14","author":"Kahraman","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2024.05.541_bib6","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.21037\/tlcr-21-206","article-title":"Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study","volume":"10","author":"Choi","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.annonc.2024.05.541_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2015.02.012","article-title":"Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib","volume":"88","author":"Wu","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2024.05.541_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12032-016-0843-8","article-title":"Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors","volume":"33","author":"Kashima","year":"2016","journal-title":"Med Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.21037\/tlcr-20-371","article-title":"The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment","volume":"10","author":"Ma","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.annonc.2024.05.541_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/tlcr-21-754","article-title":"TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib","volume":"11","author":"Roeper","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.annonc.2024.05.541_bib11","doi-asserted-by":"crossref","first-page":"V149","DOI":"10.1093\/annonc\/mdz243.015","article-title":"Association between TP53 mutations and efficacy of osimertinib for brain metastasis from EGFR-mutant lung cancer","volume":"30","author":"Chen","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib12","doi-asserted-by":"crossref","unstructured":"P\u00e9rol M, Chouaid C, Bjerrum A, et\u00a0al. Prognostic factors and outcomes of patients with advanced non\u2013small cell lung cancer while on osimertinib treatment: a retrospective database study. Presented at: the European Lung Cancer Congress (ELCC); 20-23 March 2024; Prague, Czech Republic.","DOI":"10.1016\/j.esmoop.2024.102605"},{"key":"10.1016\/j.annonc.2024.05.541_bib13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12885-022-09741-8","article-title":"Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis","volume":"22","author":"Gen","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2024.05.541_bib14","article-title":"Distinct progression and efficacy of first-line osimertinib treatment according to mutation subtypes in metastatic NSCLC harboring EGFR mutations","volume":"5","author":"Takeyasu","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.annonc.2024.05.541_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.05.541_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","article-title":"Overcoming therapy resistance in EGFR-mutant lung cancer","volume":"2","author":"Passaro","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.annonc.2024.05.541_bib17","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","article-title":"A\u00a0novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors","volume":"76","author":"Moores","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2024.05.541_bib18","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2024.05.541_bib19","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2159-8290.CD-20-0116","article-title":"Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC","volume":"10","author":"Yun","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.05.541_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of\u00a0action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.annonc.2024.05.541_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib22","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.05.541_bib23","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtho.2021.11.025","article-title":"A\u00a0phase 1\/2 study of lazertinib 240 mg in patients with advanced EGFR T790M-positive NSCLC after previous EGFR tyrosine kinase inhibitors","volume":"17","author":"Cho","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib25","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1470-2045(19)30504-2","article-title":"Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study","volume":"20","author":"Ahn","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib26","doi-asserted-by":"crossref","unstructured":"Cho BC, Lu S, Felip E, et\u00a0al. Amivantamab plus Lazertinib in Previously Untreated EGFR-mutated Advanced NSCLC. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2403614.","DOI":"10.1056\/NEJMoa2403614"},{"key":"10.1016\/j.annonc.2024.05.541_bib27","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.annonc.2024.05.541_bib28","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nbt.3391","article-title":"Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity","volume":"34","author":"Chang","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.annonc.2024.05.541_bib30","unstructured":"QIAGEN. Human Somatic Mutation Database (HSMD). https:\/\/digitalinsights.qiagen.com\/hsmd\/. Accessed March 27, 2024."},{"key":"10.1016\/j.annonc.2024.05.541_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.978069","article-title":"Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: a systematic review and meta-analysis","volume":"12","author":"Xia","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib32","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.21037\/tlcr-23-643","article-title":"Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)","volume":"12","author":"Choi","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.annonc.2024.05.541_bib33","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.18632\/oncotarget.2124","article-title":"High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients","volume":"5","author":"Canadas","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2024.05.541_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.967946","article-title":"Impact of epilepsy and its treatment on brain metastasis from solid tumors: a retrospective study","volume":"13","author":"Maschio","year":"2022","journal-title":"Front Neurol"},{"issue":"26","key":"10.1016\/j.annonc.2024.05.541_bib35","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC): results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib36","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib37","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3390\/cancers14051143","article-title":"The role of TP53 mutations in EGFR-mutated non-small-cell lung cancer: clinical significance and implications for therapy","volume":"14","author":"Canale","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2024.05.541_bib38","article-title":"Application of circulating tumor DNA as a biomarker for non-small cell lung cancer","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-017-0468-1","article-title":"Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages","volume":"10","author":"Yang","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.annonc.2024.05.541_bib40","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1158\/1078-0432.CCR-22-3146","article-title":"Early clearance of plasma epidermal growth factor receptor mutations as a predictor of outcome on osimertinib in advanced non-small cell lung cancer; exploratory analysis from AURA3 and FLAURA","volume":"29","author":"Gray","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.05.541_bib41","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N\u00a0Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424007026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424007026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T13:49:45Z","timestamp":1728308985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424007026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0923753424007026"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.05.541","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a\u00a0secondary analysis from MARIPOSA","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.05.541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}